


Spotlight on Research Fees: Study Duration in Diabetes Trials

By Rafael A Campo

As a drug progresses through clinical development, it is tested on more subjects and for longer periods of time to assess its treatment effects. In all phases except Phase II, study duration in diabetes trials decreased by an average of 10% from the period 2004-2006 to the period 2007-2009.



Notes & References

1. Study duration is defined as the planned total time an ideal subject spends in a clinical study, including screening and follow-up periods.
2. Type I and Type II diabetes trials including ancillary conditions of diabetes, e.g., wound treatment.
3. Source: Medidata Grants Manager™, the PICAS® database

Author

Rafael A Campo is the Manager of Data Quality and Analytics at Medidata Solutions, Inc. Contact him at 1.215.358.1429 or rcampo@mdsol.com.